stockportfolio.pro
Stocks / MLTX vs PAHC
MLTX vs PAHC
MoonLake Immunotherapeutics and Phibro Animal Health Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| MoonLake Immunotherapeutics (MLTX) | Phibro Animal Health Corporation (PAHC) | |
|---|---|---|
| Market cap | $1.3B | $1.3B |
| Revenue (latest FY) | $0 | $1.30B |
| Net income (latest FY) | $-227.32M | $48.30M |
| Revenue growth (5y CAGR) | — | 10.1% |
| Net margin | — | 3.7% |
| Return on equity | -74.7% | 16.9% |
| P/E ratio | — | 13.6 |
| Dividend yield | — | 1.5% |
| Profitable years (of last 10) | 0 | 10 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open MLTX — free Open PAHC — freeFrequently asked questions
Which is bigger, MLTX or PAHC?
MoonLake Immunotherapeutics is larger by market capitalization — $1.3B versus $1.3B.
Which grows faster, MLTX or PAHC?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.